Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
37
KMTS Quote, Financials, Valuation and Earnings
Last price:
$27.47
Seasonality move
:
--
Day range:
$26.90 - $27.96
52-week range:
$13.25 - $30.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.03x
P/B ratio:
7.99x
Volume:
91.1K
Avg. volume:
383.9K
1-year change:
--
Market cap:
$1.3B
Revenue:
$59.8M
EPS (TTM):
-$2.68
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KMTS
Kestra Medical Technologies Ltd.
|
$21M | -$0.57 | 52.53% | -24.76% | $29.14 |
|
AZTA
Azenta, Inc.
|
$156.4M | $0.20 | -0.42% | 86.12% | $40.17 |
|
BNGO
Bionano Genomics, Inc.
|
$6.9M | -$2.34 | -2.86% | -82.39% | $7.50 |
|
BRKR
Bruker Corp.
|
$847M | $0.32 | -2.17% | 619.12% | $51.79 |
|
HBIO
Harvard Bioscience, Inc.
|
$20M | $0.01 | -5.93% | 8650% | $2.00 |
|
PRPO
Precipio, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KMTS
Kestra Medical Technologies Ltd.
|
$27.52 | $29.14 | $1.3B | -- | $0.00 | 0% | 19.03x |
|
AZTA
Azenta, Inc.
|
$34.60 | $40.17 | $1.6B | -- | $0.00 | 0% | 2.67x |
|
BNGO
Bionano Genomics, Inc.
|
$1.56 | $7.50 | $15.8M | -- | $0.00 | 0% | 0.18x |
|
BRKR
Bruker Corp.
|
$48.13 | $51.79 | $7.3B | 77.08x | $0.05 | 0.42% | 2.13x |
|
HBIO
Harvard Bioscience, Inc.
|
$0.73 | $2.00 | $32.3M | -- | $0.00 | 0% | 0.37x |
|
PRPO
Precipio, Inc.
|
$23.89 | -- | $41.8M | -- | $0.00 | 0% | 1.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KMTS
Kestra Medical Technologies Ltd.
|
21.45% | 0.000 | 3.43% | 5.32x |
|
AZTA
Azenta, Inc.
|
3.35% | 2.112 | 4.55% | 2.22x |
|
BNGO
Bionano Genomics, Inc.
|
25.67% | -1.308 | 103.34% | 1.58x |
|
BRKR
Bruker Corp.
|
45.23% | 0.852 | 40.19% | 0.76x |
|
HBIO
Harvard Bioscience, Inc.
|
75.26% | 4.098 | 218.87% | 0.35x |
|
PRPO
Precipio, Inc.
|
20.58% | 4.591 | 11.47% | 1.19x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KMTS
Kestra Medical Technologies Ltd.
|
$11.4M | -$31.8M | -77.65% | -105.99% | -140.73% | -$25.8M |
|
AZTA
Azenta, Inc.
|
$72.3M | $2.9M | 1.39% | 1.44% | 1.85% | -$5.7M |
|
BNGO
Bionano Genomics, Inc.
|
$3.4M | -$8.5M | -58.02% | -84.77% | -115.9% | -$5.9M |
|
BRKR
Bruker Corp.
|
$399.6M | $55.2M | -0.56% | -1.2% | 6.42% | -$54.1M |
|
HBIO
Harvard Bioscience, Inc.
|
$11.2M | $245K | -68.29% | -155.33% | 1.19% | $482K |
|
PRPO
Precipio, Inc.
|
$2.6M | -$61K | -8.62% | -10.15% | -0.9% | -$44K |
Kestra Medical Technologies Ltd. vs. Competitors
-
Which has Higher Returns KMTS or AZTA?
Azenta, Inc. has a net margin of -145.29% compared to Kestra Medical Technologies Ltd.'s net margin of 32.45%. Kestra Medical Technologies Ltd.'s return on equity of -105.99% beat Azenta, Inc.'s return on equity of 1.44%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.50.63% -$0.64 $208.9M AZTAAzenta, Inc.45.4% $1.11 $1.8B -
What do Analysts Say About KMTS or AZTA?
Kestra Medical Technologies Ltd. has a consensus price target of $29.14, signalling upside risk potential of 5.9%. On the other hand Azenta, Inc. has an analysts' consensus of $40.17 which suggests that it could grow by 15.75%. Given that Azenta, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe Azenta, Inc. is more attractive than Kestra Medical Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 AZTAAzenta, Inc.1 4 0 -
Is KMTS or AZTA More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Azenta, Inc. has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.831%.
-
Which is a Better Dividend Stock KMTS or AZTA?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Azenta, Inc. pays out -- of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or AZTA?
Kestra Medical Technologies Ltd. quarterly revenues are $22.6M, which are smaller than Azenta, Inc. quarterly revenues of $159.2M. Kestra Medical Technologies Ltd.'s net income of -$32.8M is lower than Azenta, Inc.'s net income of $51.7M. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Azenta, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 19.03x versus 2.67x for Azenta, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.19.03x -- $22.6M -$32.8M AZTAAzenta, Inc.2.67x -- $159.2M $51.7M
-
Which has Higher Returns KMTS or BNGO?
Bionano Genomics, Inc. has a net margin of -145.29% compared to Kestra Medical Technologies Ltd.'s net margin of -115.42%. Kestra Medical Technologies Ltd.'s return on equity of -105.99% beat Bionano Genomics, Inc.'s return on equity of -84.77%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.50.63% -$0.64 $208.9M BNGOBionano Genomics, Inc.45.75% -$1.59 $67M -
What do Analysts Say About KMTS or BNGO?
Kestra Medical Technologies Ltd. has a consensus price target of $29.14, signalling upside risk potential of 5.9%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 390.2%. Given that Bionano Genomics, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe Bionano Genomics, Inc. is more attractive than Kestra Medical Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 BNGOBionano Genomics, Inc.1 0 0 -
Is KMTS or BNGO More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 2.336, suggesting its more volatile than the S&P 500 by 133.592%.
-
Which is a Better Dividend Stock KMTS or BNGO?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or BNGO?
Kestra Medical Technologies Ltd. quarterly revenues are $22.6M, which are larger than Bionano Genomics, Inc. quarterly revenues of $7.4M. Kestra Medical Technologies Ltd.'s net income of -$32.8M is lower than Bionano Genomics, Inc.'s net income of -$8.5M. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 19.03x versus 0.18x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.19.03x -- $22.6M -$32.8M BNGOBionano Genomics, Inc.0.18x -- $7.4M -$8.5M
-
Which has Higher Returns KMTS or BRKR?
Bruker Corp. has a net margin of -145.29% compared to Kestra Medical Technologies Ltd.'s net margin of -6.8%. Kestra Medical Technologies Ltd.'s return on equity of -105.99% beat Bruker Corp.'s return on equity of -1.2%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.50.63% -$0.64 $208.9M BRKRBruker Corp.46.44% -$0.41 $4.5B -
What do Analysts Say About KMTS or BRKR?
Kestra Medical Technologies Ltd. has a consensus price target of $29.14, signalling upside risk potential of 5.9%. On the other hand Bruker Corp. has an analysts' consensus of $51.79 which suggests that it could grow by 7.84%. Given that Bruker Corp. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe Bruker Corp. is more attractive than Kestra Medical Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 BRKRBruker Corp.7 5 1 -
Is KMTS or BRKR More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.174, suggesting its more volatile than the S&P 500 by 17.405%.
-
Which is a Better Dividend Stock KMTS or BRKR?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.42% to investors and pays a quarterly dividend of $0.05 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or BRKR?
Kestra Medical Technologies Ltd. quarterly revenues are $22.6M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Kestra Medical Technologies Ltd.'s net income of -$32.8M is higher than Bruker Corp.'s net income of -$58.5M. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 19.03x versus 2.13x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.19.03x -- $22.6M -$32.8M BRKRBruker Corp.2.13x 77.08x $860.5M -$58.5M
-
Which has Higher Returns KMTS or HBIO?
Harvard Bioscience, Inc. has a net margin of -145.29% compared to Kestra Medical Technologies Ltd.'s net margin of -5.98%. Kestra Medical Technologies Ltd.'s return on equity of -105.99% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.50.63% -$0.64 $208.9M HBIOHarvard Bioscience, Inc.54.23% -$0.03 $56.9M -
What do Analysts Say About KMTS or HBIO?
Kestra Medical Technologies Ltd. has a consensus price target of $29.14, signalling upside risk potential of 5.9%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 175.71%. Given that Harvard Bioscience, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe Harvard Bioscience, Inc. is more attractive than Kestra Medical Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 HBIOHarvard Bioscience, Inc.1 1 0 -
Is KMTS or HBIO More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.531, suggesting its more volatile than the S&P 500 by 53.123%.
-
Which is a Better Dividend Stock KMTS or HBIO?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or HBIO?
Kestra Medical Technologies Ltd. quarterly revenues are $22.6M, which are larger than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Kestra Medical Technologies Ltd.'s net income of -$32.8M is lower than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 19.03x versus 0.37x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.19.03x -- $22.6M -$32.8M HBIOHarvard Bioscience, Inc.0.37x -- $20.6M -$1.2M
-
Which has Higher Returns KMTS or PRPO?
Precipio, Inc. has a net margin of -145.29% compared to Kestra Medical Technologies Ltd.'s net margin of -1.17%. Kestra Medical Technologies Ltd.'s return on equity of -105.99% beat Precipio, Inc.'s return on equity of -10.15%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.50.63% -$0.64 $208.9M PRPOPrecipio, Inc.37.95% -$0.05 $17.3M -
What do Analysts Say About KMTS or PRPO?
Kestra Medical Technologies Ltd. has a consensus price target of $29.14, signalling upside risk potential of 5.9%. On the other hand Precipio, Inc. has an analysts' consensus of -- which suggests that it could fall by -20.46%. Given that Kestra Medical Technologies Ltd. has higher upside potential than Precipio, Inc., analysts believe Kestra Medical Technologies Ltd. is more attractive than Precipio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 PRPOPrecipio, Inc.0 0 0 -
Is KMTS or PRPO More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Precipio, Inc. has a beta of 1.085, suggesting its more volatile than the S&P 500 by 8.543%.
-
Which is a Better Dividend Stock KMTS or PRPO?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precipio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Precipio, Inc. pays out -- of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or PRPO?
Kestra Medical Technologies Ltd. quarterly revenues are $22.6M, which are larger than Precipio, Inc. quarterly revenues of $6.8M. Kestra Medical Technologies Ltd.'s net income of -$32.8M is lower than Precipio, Inc.'s net income of -$79K. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Precipio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 19.03x versus 1.63x for Precipio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.19.03x -- $22.6M -$32.8M PRPOPrecipio, Inc.1.63x -- $6.8M -$79K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
